Skip to main content
Clinical Trials/EUCTR2010-023779-24-NL
EUCTR2010-023779-24-NL
Active, not recruiting
Not Applicable

A Comparison of Drug Eluting and Bare Metal Stents with Bivalirudin during PCI or Bivalirudin for 4 hours in Acute Coronary Syndromes. The Eindhoven Reperfusion Study - The DEBATER 2 Trial

Stichting Toegepast Caridologisch Onderzoek0 sites1,800 target enrollmentNovember 11, 2010
DrugsAngiox

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Stichting Toegepast Caridologisch Onderzoek
Enrollment
1800
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 11, 2010
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Stichting Toegepast Caridologisch Onderzoek

Eligibility Criteria

Inclusion Criteria

  • STEMI \< 12 hours (or STE equivalent), or NSTEMI \< 48 hours
  • No contraindications for PCI
  • No contraindications for abciximab
  • No contraindications for clopidogrel
  • Informed consent from the patient
  • Criteria for STEMI \< 12 hours (or STE equivalent)
  • Continual chest discomfort of acute onset within the last 12 hours
  • \= 1 mm ST\-segment elevation in \= 2 contiguous ECG leads
  • STE equivalent
  • \= 1 mm ST\-segment depression in ECG leads V1\-V3 (reversed ST\-segment elevations of the posterior wall)

Exclusion Criteria

  • Contraindication for PCI: peripheral/coronary artery disease that is inaccessible for PCI
  • Contraindication for GPI: ongoing bleeding, bleeding diathesis, cerebrovascular accident in the last 6 months, major surgery/trauma in the last 6 months, platelet count \< 100\.000 mm3, intracranial intravenous malformation or neoplasm, malignant hypertension, INR . 1\.5, severe hepatic dysfunction
  • Contraindication for bivalirudin: bleeding diathesis, thrombocytopathy, thrombocytopenia, coagulopathy, recent surgery, TIA or CVA, severe uncontrolled hypertension, active peptic ulcer, severe renal insufficiency (MDRD \< 30 ml/min).
  • Contraindication for clopidogrel: severe hepatic dysfunction, pathological bleeding
  • disorders such as peptic ulcer or intracranial bleeding
  • Thrombolytic therapy within the last 24 hours
  • Therapy with GPI within the last 24 hours
  • Anticoagulation therapy
  • C\-morbid conditions with a predictable fatal outcome in the short run
  • No informed consent: refusal, (sub) coma, artificial respiration, impaired mentation

Outcomes

Primary Outcomes

Not specified

Similar Trials